About this trial
The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention.
The main questions it aims to answer are:
Does the intervention improve insulin sensitivity (how the body uses glucose)?
Does the intervention improve cognition, measured by the Montreal Cognitive Assessment (MoCA) and the Revised Memory and Behavior Problems Checklist (RMBPC)?
What changes occur in brain glucose uptake (FDG-PET)?
Participants will:
Receive the intervention once a week for 6 months, with each session lasting up to 2 hours
Complete cognitive assessments. Adverse events will be assessed throughout the study.
Eligibility criteria
Qualifiers
Mini Mental State Examination (MMSE) score < 25
Disqualifiers
On daily medication for the specific treatment of anxiety including benzodiazepines.
An infant, child, or teenager
A pregnant woman
A prisoner
Trial design
Treatments tested in this trial
- Physiological Insulin Intervention
Treatment groups
Locations
1Sponsors and collaborators
Pennington Biomedical Research Center
Lead sponsor